Health outcomes, education, healthcare delivery and quality – 3052. IL-17, IL-18, TGF-beta and GMCSF levels in patients with allergic asthma: Its relation to omalizumab treatment

Documenti analoghi

• Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
  di: Yalcin, Arzu Didem, et al.
  Pubblicazione: (2013)
• Serum-soluble TRAIL levels in patients with severe persistent allergic asthma: Its relation to omalizumab treatment
  di: Yalcin, Arzu Didem, et al.
  Pubblicazione: (2012)
• 277 Serum Soluble Trail Levels in Patients With Severe Persistent Allergic Asthma: Its Relation to Omalizumab Treatment
  di: Yalcin, Arzu Didem, et al.
  Pubblicazione: (2012)
• IL-8, IL-10, TGF-β, and GCSF Levels Were Increased in Severe Persistent Allergic Asthma Patients with the Anti-IgE Treatment
  di: Yalcin, Arzu D., et al.
  Pubblicazione: (2012)
• Mechanisims of asthma and allergic disease – 1066. Ceruloplasmin oxidase activity in allergic asthma and allergic rhinitis
  di: Yalcin, Arzu Didem, et al.
  Pubblicazione: (2013)